$275 Million is the total value of Affinity Asset Advisors, LLC's 55 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 88.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MORF | Buy | MORPHIC HLDG INC | $18,919,000 | +23.4% | 399,302 | +47.5% | 6.87% | +77.4% |
| SWTX | Buy | SPRINGWORKS THERAPEUTICS INC | $18,504,000 | +131.5% | 298,545 | +136.9% | 6.72% | +232.8% |
| SAVA | Buy | CASSAVA SCIENCES INCput | $15,295,000 | +228.5% | 350,000 | +366.7% | 5.55% | +372.3% |
| VINC | Buy | VINCERX PHARMA INC | $11,569,000 | -28.8% | 1,135,365 | +13.0% | 4.20% | +2.4% |
| ZNTL | Buy | ZENTALIS PHARMACEUTICALS INC | $9,877,000 | +91.2% | 117,500 | +51.6% | 3.59% | +175.1% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $9,294,000 | – | 100,000 | +100.0% | 3.38% | – |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $9,055,000 | +854.2% | 555,155 | +646.8% | 3.29% | +1270.0% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $8,246,000 | – | 241,119 | +100.0% | 2.99% | – |
| KURA | Buy | KURA ONCOLOGY INC | $7,840,000 | -21.0% | 560,000 | +5.7% | 2.85% | +13.6% |
| MRNA | New | MODERNA INCput | $7,619,000 | – | 30,000 | +100.0% | 2.77% | – |
| NVAX | New | NOVAVAX INCput | $7,154,000 | – | 50,000 | +100.0% | 2.60% | – |
| CYTK | Buy | CYTOKINETICS INC | $6,634,000 | +48.5% | 145,552 | +16.4% | 2.41% | +113.6% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $5,816,000 | -7.7% | 400,000 | +14.3% | 2.11% | +32.7% |
| RPTX | New | REPARE THERAPEUTICS INC | $5,732,000 | – | 271,778 | +100.0% | 2.08% | – |
| New | BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $5,529,000 | – | 7,500,000 | +100.0% | 2.01% | – | |
| MDGL | New | MADRIGAL PHARMACEUTICALS INC | $5,508,000 | – | 65,000 | +100.0% | 2.00% | – |
| NAUT | Buy | NAUTILUS BIOTECHNOLOGY INC | $5,438,000 | -9.2% | 1,049,721 | +7.7% | 1.98% | +30.6% |
| ESTA | Buy | ESTABLISHMENT LABS HLDGS INC | $5,238,000 | +22.0% | 77,500 | +29.2% | 1.90% | +75.3% |
| CRIS | New | CURIS INCcall | $4,998,000 | – | 1,050,000 | +100.0% | 1.82% | – |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $4,720,000 | +39.1% | 419,144 | +106.3% | 1.71% | +100.0% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $4,702,000 | +515.4% | 150,500 | +201.0% | 1.71% | +784.5% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $3,864,000 | +78.2% | 100,000 | +149.0% | 1.40% | +156.0% |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $3,831,000 | – | 175,000 | +100.0% | 1.39% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $3,793,000 | – | 1,122,244 | +100.0% | 1.38% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $3,602,000 | +50.2% | 165,000 | +105.7% | 1.31% | +115.8% |
| CRIS | Buy | CURIS INC | $3,094,000 | -31.3% | 650,000 | +13.0% | 1.12% | -1.1% |
| Buy | PROCEPT BIOROBOTICS CORP | $2,501,000 | -16.5% | 100,000 | +27.3% | 0.91% | +19.9% | |
| New | SCIENCE 37 HOLDINGS INC | $1,871,000 | – | 150,000 | +100.0% | 0.68% | – | |
| CVAC | New | CUREVAC N Vcall | $1,716,000 | – | 50,000 | +100.0% | 0.62% | – |
| ARKG | New | ARK ETF TRcall | $1,531,000 | – | 25,000 | +100.0% | 0.56% | – |
| INO | New | INOVIO PHARMACEUTICALS INCcall | $998,000 | – | 200,000 | +100.0% | 0.36% | – |
| Buy | RENOVACOR INC | $963,000 | -7.5% | 125,000 | +8.7% | 0.35% | +33.1% | |
| New | HYPERFINE INC | $552,000 | – | 76,162 | +100.0% | 0.20% | – | |
| New | LIANBIO SPONSOREDads | $446,000 | – | 72,406 | +100.0% | 0.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-07 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.